Adalimumab originator versus adalimumab biosimilars in inflammatory bowel disease in Australia.
Sign Up to like & getrecommendations! Published in 2023 at "Expert opinion on biological therapy"
DOI: 10.1080/14712598.2023.2203812
Abstract: BACKGROUND Biosimilar adalimumabs have improved treatment access, but without any clinical advantage, distributors rely on delivery device design-enhancements, support services, and removal of painful excipients to capture market share. Prescribers, however, are often unaware of… read more here.
Keywords: originator versus; adalimumab biosimilars; versus adalimumab; adalimumab ... See more keywords
Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study
Sign Up to like & getrecommendations! Published in 2022 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/ard-2022-222824
Abstract: Objectives To assess the risk of major adverse cardiovascular events (MACEs) and venous thromboembolism events (VTEs) among patients initiating a Janus kinase inhibitor (JAKi) (tofacitinib and baricitinib) versus adalimumab in a large real-world population of… read more here.
Keywords: rheumatoid arthritis; cardiovascular; versus adalimumab; cohort ... See more keywords
Cost per Responder Analysis of Secukinumab versus Adalimumab in the Treatment of Psoriatic Disease
Sign Up to like & getrecommendations! Published in 2022 at "Vaccines"
DOI: 10.3390/vaccines10050646
Abstract: Background: The EXCEED study evaluated the efficacy and safety of secukinumab versus adalimumab in psoriatic arthritis, but it did not include a pharmacoeconomic analysis. The objective of this study was to compare the cost per… read more here.
Keywords: cost per; secukinumab; responder; secukinumab versus ... See more keywords